Lawrence, who also serves as Acorda’s principal accounting and financial officer, is resigning effective mid-March 2021 as he is set to take a leadership position at an early-stage biotechnology company, according to a news release.
“Dave has been an important part of Acorda’s leadership team over the past 22 years and we are grateful for the many contributions he has made to the company,” Acorda president & CEO Ron Cohen said in the release. “While we will miss him, we support his interest in exploring a new phase of his career, and wish him well in his next opportunity.”
Ardsley, N.Y.-based Acorda’s VP of finance & controller, Robert Morales, is set to take over Lawrence’s roles as the interim principal accounting officer and interim principal financial officer.
“I am proud to have been part of helping Acorda grow from a small, private company to a public, commercial company that has brought important new therapies to people living with neurological conditions, including Parkinson’s and multiple sclerosis,” Lawrence said. “Following our recently announced improvements to Acorda’s financial structure, I am leaving the company in an excellent position, and will be cheering it on to continued success.”
Acorda develops therapies designed to restore function and improve the lives of those with neurological disorders. Its Inbrija therapeutic is approved for intermittent treatment of off-episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.
Inbrija uses Acorda’s Arcus pulmonary delivery system, a platform designed to deliver the medication through inhalation.